Outcome | Author | Patient characteristics | Score | Calculated effect size (d) | |
---|---|---|---|---|---|
Pre-ACLR | Six months post-ACLR | ||||
IKDC-SKF | Raoul, et al. [26] | - | 62.0 ± 14.3 | 76.1 ± 11.9 | 1.07b |
Magnitskaya, et al. [17] | - | 65 (54–77)a | 80 (68–89)a | -b | |
TSK-11 | Hartigan, et al. [8] | Non-coper | 26.0 ± 6.5 | 15.6 ± 3.4 | 2.01b |
Coper | 22.6 ± 5.5 | 17.8 ± 4.8 | 0.93b | ||
Rhim, et al. [27] | Intervention | 25.9 ± 3.4 | 24.5 ± 3.9 | 0.38 | |
Placebo | 24.6 ± 7.2 | 20.7 ± 6.3 | 0.58 | ||
Control | 25.0 ± 4.5 | 23.3 ± 5.5 | 0.34 | ||
ACL-RSI | Raoul, et al. [26] | - | 40.2 ± 22.1 | 60.2 ± 20.9 | 0.93b |
Sadeqi, et al. [28] | - | 41.3 ± 25.4 | 58.3 ± 22.3 | 0.71b | |
Rhim, et al. [27] | Intervention | 52.3 ± 11.7 | 59.0 ± 13.6 | 0.53 | |
Placebo | 50.9 + 23.2 | 62.6 ± 27.8 | 0.46 | ||
Control | 60.8 ± 16.0 | 66.3 ± 11.6 | 0.39 |